Curasight A/S
16 Sep - 7 Oct 2021Warrent exercise
Curasight is a Danish biotech company pioneering in the development of intelligent cancer imaging and more gentle and efficient treatment of cancer, using nuclear medicine. Curasight’s novel uPAR Theranostics technology is based on more than 10 years of research at Rigshospitalet in Copenhagen by Professor Andreas Kjær and his group. The technology minimizes irradiation of healthy tissue by combining the targeted uTREAT® radiation therapy, with the precise uTRACE® diagnostics. Curasight‘s imaging technology is now tested in a broad pipeline of investigator-initiated phase II clinical trials.
Read more at the company's website
The offer in summary
Exercise period: September 16th, 2021 - October 7th, 2021
Trading in warrants: Until October 5th, 2021
Subsription price: DKK 17.20
Payment date: October 7th, 2021
About the warrant: One (1) TO 1 warrent will be traded to one (1) stock.
Please notice! If you are a Danish investor with your warrants held in Nordnet, your subscription and payment shall be made through the bank.
